Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

GSK


Top 10 Correlated ETFs

GSK


Top 10 Correlated Stocks

GSK


In the News

11:58 04 Oct 2022 GSK

GSK board appointment is positive says broker but focus is on weak GBP, Zantac legals

The rise in GSK PLC (LSE:GSK, NYSE:GSK) shares on the reporting of a finance chief was probably more to do with the slide in sterling, than the market's excitement about the creation of an all-female top team, said Barclays. Following the drug maker announcing that Julie Brown is being poached from Burberry to take the role of chief financial officer as Iain Mackay retires, the general reception to the news today has been positive, the bank said.

09:54 04 Oct 2022 GSK

AstraZeneca, BAT, Ferguson, 4imprint and other exporters get double-benefit from sterling crash

As the pound crashed following Kwasi Kwarteng's quasi-infamous ‘mini' budget, many crafty currency speculators made a quick fortune, while savvy stock market investors are still mulling which companies are likely to benefit most. Sterling has never been so weak, which in theory should make products sold by UK exporters potentially very much more attractive.

04:58 04 Oct 2022 GSK

GSK poaches Burberry CFO to complete rare all-female executive leadership team

GSK PLC (LSE:GSK, NYSE:GSK) poached Burberry Group PLC (LSE:BRBY)'s chief financial officer (CFO) Julie Brown to complete a rare but all-female executive leadership team. Brown will replace Iain Mackay, who has been finance chief at the FTSE-100 pharmaceuticals giant since 2019.

02:06 04 Oct 2022 GSK

GSK picks Burberry's Brown as first female CFO

GSK named luxury fashion brand Burberry's Julie Brown as its first ever female chief financial officer on Monday to succeed Iain Mackay, at a time when the British drugmaker is sharpening focus on its core business.

12:35 04 Oct 2022 GSK

GSK poaches Burberry CFO Julie Brown to create all-female top team - Sky News

British drugmaker GSK plc , has poached Burberry Group's finance chief to create a rare all-female executive leadership team, Sky News reported on Saturday.

04:55 04 Oct 2022 GSK

7 Stocks to Buy That Can Soar in Good Times or in Bad

Many commentators, analysts, and economists are convinced that the U.S. will enter a recession next year. Given the strength of the labor market and of corporate balance sheets, along with the onshoring phenomenon and the many jobs that the energy transition is creating, I have my doubts as to whether a recession is on the way.

10:53 04 Oct 2022 GSK

Spero's stock jumps 188% after GSK licenses experimental antibiotic

Shares of Spero Therapeutics Inc. SPRO, +277.39% soared 188.4% in trading on Thursday morning after the company signed an exclusive license agreement with GlaxoSmithKline GSK, -0.32% for its experimental antibiotic for complicated urinary tract infections. Spero's therapy, tebipenem HBr, is expected to enter Phase 3 clinical trials next year.

02:57 04 Oct 2022 GSK

GSK to shell out an initial US$75mln to gain rights to a next-generation antibiotic

GSK PLC (LSE:GSK, NYSE:GSK) has inked a licensing deal with a Cambridge, Massachusetts, biotech that will give it access to an oral antibiotic for complicated urinary tract infections. The UK group is paying Spero Therapeutics Inc an initial US$66mln to licence the latter's tebipenem pivoxil hydrobromide, which is about to enter phase III clinical trials.

10:32 04 Oct 2022 GSK

Is Trending Stock GSK PLC Sponsored ADR (GSK) a Buy Now?

Glaxo (GSK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

10:45 04 Oct 2022 GSK

2 Dividend Stocks to Double Up On Right Now

These pharma giants are ideal for long-term investors because of their consistent growth and above-average dividend yields.

Financial details

Company Rating
Strong Buy
Market Cap
57.98B
Income
4.56B
Revenue
35.31B
Book val./share
10.17
Cash/share
4.06
Dividend
1.62
Dividend %
7.54%
Employees
90.1K
Optionable
Yes
Shortable
Yes
Earnings
01 Feb 2017
P/E
11.96
Forward P/E
-
PEG
-6.67
P/S
0.98
P/B
2.11
P/C
7.47
P/FCF
4.57
Quick Ratio
0.17
Current Ratio
1.43
Debt / Equity
1.15
LT Debt / Equity
0.83
-
-
EPS (TTM)
2.37
EPS next Y
-
EPS next Q
-
EPS this Y
-24.16%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
22.78%
Revenue last 5Y
2.48%
Revenue Q/Q
-29.15%
EPS Q/Q
-42.06%
-
-
-
-
SMA20
-12.12%
SMA50
-25.64%
SMA100
-35.56%
Inst Own
6.71%
Inst Trans
0.17%
ROA
5%
ROE
29%
ROC
0.13%
Gross Margin
65%
Oper. Margin
19%
Profit Margin
13%
Payout
57%
Shs Outstand
2.03B
Shs Float
1.96B
-
-
-
-
Target Price
55
52W Range
28.47-46.97
52W High
-34.03%
52W Low
+8.38%
RSI
32
Rel Volume
0.79
Avg Volume
6.87M
Volume
5.43M
Perf Week
1.12%
Perf Month
-10.91%
Perf Quarter
-35.97%
Perf Half Y
-32.19%
-
-
-
-
Beta
0.258812
-
-
Volatility
0.5%, 1.54%
Prev Close
3.11%
Price
30.345
Change
3%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
15.4515.6817.0617.1317.05
Net income per share
0.781.842.352.892.19
Operating cash flow per share
3.544.284.054.243.97
Free cash flow per share
2.413.372.963.122.51
Cash per share
22.012.423.12.07
Book value per share
-0.032.225.767.337.52
Tangible book value per share
-10.13-9.83-11.7-9.85-9.64
Share holders equity per share
-0.032.225.767.337.52
Interest debt per share
9.1213.6515.8614.0712.47
Market cap
55.44B56.63B69.19B55.18B67.4B
Enterprise value
68.69B78.82B94.99B76.24B87.5B
P/E ratio
36.1915.6314.99.615.37
Price to sales ratio
1.841.842.051.621.98
POCF ratio
8.016.738.636.548.48
PFCF ratio
11.758.5511.818.913.42
P/B Ratio
-815.2412.996.073.784.48
PTB ratio
-815.2412.996.073.784.48
EV to sales
2.282.562.812.242.56
Enterprise value over EBITDA
12.3911.2510.77811.1
EV to operating cash flow
9.939.3611.849.0311
EV to free cash flow
14.5711.916.2212.2917.43
Earnings yield
0.030.060.070.10.07
Free cash flow yield
0.090.120.080.110.07
Debt to equity
-209.764.652.071.611.37
Debt to assets
0.940.940.770.740.73
Net debt to EBITDA
2.393.172.932.212.55
Current ratio
0.60.750.810.910.79
Interest coverage
5.557.117.879.097.98
Income quality
4.522.321.731.471.81
Dividend Yield
0.070.070.060.070.06
Payout ratio
2.551.080.850.690.91
Sales general and administrative to revenue
0.320.320.340.340.32
Research and developement to revenue
0.150.130.140.150.15
Intangibles to total assets
0.410.40.520.50.51
Capex to operating cash flow
-0.32-0.21-0.27-0.27-0.37
Capex to revenue
-0.07-0.06-0.06-0.07-0.09
Capex to depreciation
-1.15-0.97-0.93-0.95-1.23
Stock based compensation to revenue
0.010.010.010.010.01
Graham number
0.789.5917.4521.8219.26
ROIC
0.140.150.130.130.11
Return on tangible assets
0.050.10.120.140.11
Graham Net
-23.64-24.27-27.07-25.35-25.35
Working capital
-10.66B-5.56B-4.56B-1.9B-5B
Tangible asset value
-19.81B-19.32B-23.16B-19.61B-19.29B
Net current asset value
-36.99B-37.47B-41.84B-39.38B-39.09B
Invested capital
-251.315.982.671.861.61
Average receivables
00000
Average payables
3.94B4B4.25B4.36B4.45B
Average inventory
5.78B5.74B5.97B6B5.89B
Days sales outstanding
00000
Days payables outstanding
124.51129.91127.5135.88142.66
Days of inventory on hand
196.12195.17182.98186.99181.92
Receivables turnover
00000
Payables turnover
2.932.812.862.692.56
Inventory turnover
1.861.871.991.952.01
ROE
-22.530.830.410.390.29
Capex per share
-1.13-0.91-1.09-1.12-1.46

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-06-30
Revenue per share
4.044.534.744.874.3
Net income per share
0.70.580.370.90.52
Operating cash flow per share
0.651.281.881.271.02
Free cash flow per share
0.320.641.560.970.75
Cash per share
1.781.752.066.964.06
Book value per share
7.687.77.58.0610.17
Tangible book value per share
-9.09-9.52-9.61-9.233.33
Share holders equity per share
7.687.77.58.0610.17
Interest debt per share
12.8312.8812.1316.713.86
Market cap
59.32B56.96B65.91B65.1B52.16B
Enterprise value
81.3B79.11B86.01B87.46B67.81B
P/E ratio
10.6312.19229.0315.56
Price to sales ratio
7.336.286.926.667.53
POCF ratio
45.9222.2317.525.6131.9
PFCF ratio
94.0144.5721.0233.5443.15
P/B Ratio
3.863.694.384.023.19
PTB ratio
3.863.694.384.023.19
EV to sales
10.058.729.038.949.79
Enterprise value over EBITDA
37.2428.9480.0127.7737.2
EV to operating cash flow
62.9330.8822.8334.4141.47
EV to free cash flow
128.8561.927.4345.0656.09
Earnings yield
0.020.020.010.030.02
Free cash flow yield
0.010.020.050.030.02
Debt to equity
1.331.341.371.811.15
Debt to assets
0.720.720.730.750.75
Net debt to EBITDA
10.078.118.77.18.58
Current ratio
0.820.810.791.191.43
Interest coverage
8.729.694.8613.215.3
Income quality
0.932.195.031.411.95
Dividend Yield
0.020.020.010.010.02
Payout ratio
0.830.811.270.531.38
Sales general and administrative to revenue
0.330.290.340.290.3
Research and developement to revenue
0.150.160.150.120.18
Intangibles to total assets
0.520.520.510.460.19
Capex to operating cash flow
-0.51-0.5-0.17-0.24-0.26
Capex to revenue
-0.08-0.14-0.07-0.06-0.06
Capex to depreciation
-1-1.3-1.73-0.85-0.68
Stock based compensation to revenue
00000
Graham number
10.9810.057.9312.7610.91
ROIC
0.030.030.020.040.02
Return on tangible assets
0.040.030.020.040.01
Graham Net
-24.33-25.12-25.27-24.94-35.74
Working capital
-3.82B-4.16B-5B4.71B16.35B
Tangible asset value
-18.19B-19.08B-19.29B-18.54B5.36B
Net current asset value
-37.87B-38.69B-39.09B-38.07B-12.22B
Invested capital
1.661.661.612.061.35
Average receivables
00000
Average payables
15.92B16.4B11.06B17.58B16.19B
Average inventory
6.17B6.12B5.89B6B5.33B
Days sales outstanding
00000
Days payables outstanding
502.75474.45110.91428.71612.38
Days of inventory on hand
223.06194.52141.43146.41192.9
Receivables turnover
00000
Payables turnover
0.180.190.810.210.15
Inventory turnover
0.40.460.640.610.47
ROE
0.090.080.050.110.05
Capex per share
-0.33-0.64-0.31-0.3-0.26

Frequently Asked Questions

What is GlaxoSmithKline plc stock symbol ?

GlaxoSmithKline plc is a GB stock and trading under the symbol GSK

What is GlaxoSmithKline plc stock quote today ?

GlaxoSmithKline plc stock price is $30.345 today.

Is GlaxoSmithKline plc stock public?

Yes, GlaxoSmithKline plc is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap